natgillin/translations-raw huggingface dataset:
Treatment with Temozolomide Accord should be prescribed by a doctor with experience in the treatment of brain tumours.
Zdravljenje z zdravilom Temozolomide Accord mora predpisati zdravnik, ki ima izkušnje z zdravljenjem možganskih tumorjev.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Accord.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Because Temozolomide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Temozolomide Accord generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Temozolomide Accord has been shown to have comparable quality and to be bioequivalent to Temodal.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Temozolomide Accord primerljivo raven kakovosti kot zdravilo Temodal ter mu je biološko enakovredno.
Other information about Temozolomide Accord:
Druge informacije o zdravilu Temozolomide Accord:
What are the benefit and risk of Temozolomide Accord?
Kakšne so koristi in tveganja, povezani z zdravilom Temozolomide Accord?
Because Temozolomide Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Ker je zdravilo Temozolomide Accord generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Temodal.
Temozolomide Accord is used on its own in these patients.
Pri teh bolnikih se zdravilo Temozolomide Accord uporablja samostojno.
The active substance in Temozolomide Accord, temozolomide, belongs to a group of cancer medicines called alkylating agents.
Zdravilna učinkovina zdravila Temozolomide Accord, temozolomid, spada v skupino zdravil proti raku, imenovanih alkilirajoči citostatiki.
Temozolomide Accord is a cancer medicine that contains the active substance temozolomide.
Temozolomide Accord je zdravilo proti raku, ki vsebuje zdravilno učinkovino temozolomid.
The dose of Temozolomide Accord depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day.
Odmerek zdravila Temozolomide Accord je odvisen od telesne površine (izračunane glede na telesno višino in maso bolnika) in sega od 75 do 200 mg na kvadratni meter, enkrat na dan. Odmerek in število odmerkov sta odvisna od vrste zdravljenega tumorja ter od tega, ali je bil bolnik že zdravljen, ali se zdravilo Temozolomide Accord uporablja samostojno ali skupaj z drugimi zdravljenji in kako se bolnik odziva na zdravljenje.
Why has Temozolomide Accord been approved?
Zakaj je bilo zdravilo Temozolomide Accord odobreno?
Patients may also need to take medicines to prevent vomiting before taking Temozolomide Accord.
Preden bo bolnik vzel zdravilo Temozolomide Accord, bo morda potreboval tudi zdravilo za preprečevanje bruhanja.
How has Temozolomide Accord been studied?
Kako je bilo zdravilo Temozolomide Accord raziskano?
What is Temozolomide Accord used for?
Za kaj se zdravilo Temozolomide Accord uporablja?
What is Temozolomide Accord?
Kaj je zdravilo Temozolomide Accord?
How does Temozolomide Accord work?
Kako zdravilo Temozolomide Accord deluje?
How is Temozolomide Accord used?
Kako se zdravilo Temozolomide Accord uporablja?
The Committee recommended that Temozolomide Accord be given marketing authorisation.
Zato je menil, da tako kot pri zdravilu Temodal koristi odtehtajo znana tveganja in priporočil, da se za zdravilo Temozolomide Accord izda dovoljenje za promet.
Date of first authorisation: 15 January 2015 Date of latest renewal: 03 September 2019
Datum prve odobritve: 15. januar 2015 Datum zadnjega podaljšanja: 03. september 2019
You may see a small air bubble, which is normal.
Morda lahko vidite majhen zračni mehurček, kar je normalno.
Your doctor will decide if and when you may restart the treatment.
Zdravnik bo določil če in kdaj lahko ponovno začnete z zdravljenjem.
• if you have tuberculosis.
• če imate tuberkulozo;
Correct Incorrect
pravilno nepravilno
• if you have long-term or repeated infections.
• če imate katero od dolgotrajnih ali ponavljajočih se okužb;
• if you have ever had an allergic reaction to latex.
• če ste imeli kdaj alergijsko reakcijo na lateks
These improvements were maintained for 52 weeks (studies 1 and 2).
Navedena izboljšanja so vztrajala 52 tednov (v 1. in 2. študiji).
Such signs are listed under “Serious side effects” in section 4.
Omenjeni znaki so navedeni pod naslovom "Resni neželeni učinki" v poglavju 4.
Improvements were shown in all components of the ACR scores, including patient assessment of pain.
Do izboljšanja je prišlo pri vseh ocenah po kriterijih ACR, vključno z bolnikovo oceno bolečine.
• if you have an active infection which your doctor thinks is important.
• če imate aktivno okužbo, ki se zdi vašemu zdravniku pomembna.
• if you have Crohn's disease.
• če imate Crohnovo bolezen;
For all of the above indications, available data suggest that a clinical response is usually achieved within 16 weeks of treatment.
Po razpoložljivih podatkih pri vseh zgoraj navedenih indikacijah pride do kliničnega odziva običajno v 16 tednih zdravljenja.
Of these, over 11,700 patients were exposed to secukinumab for at least one year.
Med njimi je bilo več kot 11.700 bolnikov izpostavljenih sekukinumabu najmanj eno leto.
Quality of life/patient-reported outcomes
Kakovost življenja/izidi po navedbah bolnikov
Possible serious infection - the signs may include:
Možnost resne okužbe - znaki lahko vključujejo:
• severe allergic reaction with shock (anaphylactic reaction)
• huda alergijska reakcija s šokom (anafilaktična reakcija)
The preparation time from piercing the stopper until end of reconstitution takes 20 minutes on average and should not exceed 90 minutes.
Čas priprave od prebadanja zaporke do zaključka rekonstitucije traja v povprečju 20 minut, ne sme pa trajati dlje kot 90 minut.
There were no reported cases of more severe neutropenia.
O primerih hujše nevtropenije niso poročali.
The safety and efficacy of Cosentyx in children below the age of 18 years have not yet been established.
Varnost in učinkovitost zdravila Cosentyx pri otrocih, starih manj kot 18 let, še nista bili dokazani.
Cosentyx is not recommended for children and adolescents (under 18 years of age) because it has not been studied in this age group.
Uporaba zdravila Cosentyx ni priporočljiva za otroke in mladostnike (stare manj kot 18 let), ker je v tej starostni skupini niso proučevali.
In addition, one study assessed a chronic treatment regimen versus a “retreatment as needed” regimen [SCULPTURE].
V eni študiji so poleg tega ocenjevali tudi režim kroničnega zdravljenja v primerjavi z režimom "ponovitve zdravljenja po potrebi" [študija SCULPTURE].
Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.
Zdravnik bo redno pregledoval vaše stanje in preverjal, ali je zdravljenje tako učinkovito, kot je treba.
Serious allergic reaction - the signs may include:
Resne alergijske reakcije - znaki lahko vključujejo:
Exposure was dose proportional across all dosing regimens.
Izpostavljenost učinkovini je bila sorazmerna višini odmerka pri vseh režimih odmerjanja.
All patients were followed for up to 52 weeks following first administration of study treatment.
Vse bolnike so spremljali do 52 tednov po prvem odmerjanju preučevanega zdravila.
Elderly patients (aged 65 years and over) No dose adjustment is required (see section 5.2).
Starejši bolniki (stari 65 let ali več) Prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
Across studies, absolute bioavailabilities in the range between 60 and 77% were calculated.
Po podatkih več študij znaša absolutna biološka uporabnost med 60 % in 77 %.
Vials are for single use only.
Viale so samo za enkratno uporabo.
Remove the plastic cap from the vial.
Z viale snemite plastični pokrovček.
• if you have ulcerative colitis.
• če imate ulcerozni kolitis;
Secukinumab has the potential to increase the risk of infections.
Sekukinumab lahko poveča tveganje za razvoj okužb.
• if you currently have an infection
• če trenutno prebolevate okužbo
• if you are taking, have recently taken or might take any other medicines.
• če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo,
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the Instructions for Use in the package leaflet.
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.6 in Navodila za uporabo v priloženem navodilu.
Chemical and physical in-use stability has been demonstrated for 24 hours at 2ºC to 8ºC.
Kemijsko in fizikalno stabilnost pripravljenega zdravila so dokazali za 24 ur pri 2 °C do 8 °C.
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).
Pri tem ustrezna kategorija pogostnosti posameznega neželenega učinka temelji na naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Week 24
teden 24
Improvements in HAQ-DI scores were seen regardless of previous anti-TNFα exposure.
Izboljšanje ocene HAQ-DI so opažali ne glede na predhodno izpostavljenost zaviralcu TNFα.
Then talk to your doctor to discuss when you should inject the next dose.
Nato se posvetujte z zdravnikom, kdaj si morate injicirati naslednji odmerek.
YOU MUST READ THIS BEFORE INJECTING.
TO MORATE PREBRATI PRED INJICIRANJEM
This is intended to aid in the protection of healthcare professionals, patients who self-inject doctor-prescribed medicines, and individuals who assist self-injecting patients from accidental needlestick injuries.
To je namenjeno zaščiti zdravstvenih delavcev, bolnikov, ki si sami injicirajo zdravila, ki jim jih predpiše zdravnik, in oseb, ki bolnikom pomagajo pri samoinjiciranju, pred poškodbami zaradi nehotenega vboda z iglo.
• infection of the external ear (otitis externa)
• vnetje zunanjega ušesa (otitis externa)
The safety profile of secukinumab is consistent across all indications.
Varnostni profil sekukinumaba je podoben pri vseh indikacijah.
Cosentyx can potentially cause serious side effects, including infections and allergic reactions.
Zdravilo Cosentyx lahko povzroči resne neželene učinke, med drugim okužbe in alergijske reakcije.
If you have active psoriatic arthritis you will first be given other medicines.
Če imate aktiven psoriatični artritis, boste najprej prejemali druga zdravila.
The preparation of the solution for subcutaneous injection must be done without interruption and ensuring that aseptic technique is used.
Pripravljanje raztopine za subkutano injiciranje mora potekati brez prekinitev, izvajati pa ga je treba z aseptično tehniko.
Clinically important, active infection, e.g. active tuberculosis (see section 4.4).
Klinično pomembna aktivna okužba, na primer aktivna tuberkuloza (glejte poglavje 4.4).
The stream of sterile water for injections should be directed onto the powder.
Tok sterilne vode za injekcije mora biti usmerjen na prašek.
** p values versus etanercept: p=0.0250
** vrednost p v primerjavi z etanerceptom: p=0,0250
Similar responses were seen in PsA study 1.
Podobne odzive so opažali tudi v PsA študiji 1.
These improvements were sustained up to week 52.
Ta izboljšanja so se ohranila do konca 52. tedna.
Women of childbearing potential should use an effective method of contraception during treatment and for at least 20 weeks after treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še najmanj 20 tednov po njem.
• if you are allergic to secukinumab or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na sekukinumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The data suggest that secukinumab does not suppress the humoral immune response to the meningococcal or influenza vaccines.
Podatki kažejo, da sekukinumab ne zavira humoralnega imunskega odziva na meningokokno cepivo oziroma cepivo proti gripi.
The majority of patients also had active psoriasis skin lesions or a documented history of psoriasis.
Večina bolnikov je imela tudi aktivne psoriatične kožne lezije ali dokumentirano anamnezo psoriaze.
If you have ankylosing spondylitis you will first be given other medicines.
Če imate ankilozirajoči spondilitis, boste najprej prejemali druga zdravila.
• swelling of the face, lips, tongue or throat
• otekanje v obraz, ustnice, jezik ali grlo oziroma žrelo,
The efficacy and safety of secukinumab 150 mg and 300 mg were evaluated versus either placebo or etanercept.
Učinkovitost in varnost sekukinumaba v odmerkih 150 mg in 300 mg so vrednotili v primerjavi z bodisi placebom ali etanerceptom.
The effect of secukinumab on human fertility has not been evaluated.
Vpliva sekukinumaba na plodnost pri ljudeh niso ocenjevali.
For storage conditions after reconstitution of the medicinal product, see section 6.3
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Not known (frequency cannot be estimated from the available data): • fungal infections of the skin and mucous membranes (including oesophageal candidiasis)
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov): • glivične okužbe kože in sluznic (vključno s kandidozo požiralnika)
9/l (CTCAE grade 4) were reported.
9/l (stopnje 4 po CTCAE).
Do not use Cosentyx:
Ne uporabljajte zdravila Cosentyx:
Any remaining solution in the vial must not be used and should be discarded in accordance with local requirements.
Morebitnega preostanka raztopine v viali ne smete uporabiti, ampak ga morate zavreči v skladu z lokalnimi zahtevami.
Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC10
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci interlevkinov, oznaka ATC: L04AC10
Cosentyx reduces the inflammation and other symptoms of the disease.
Zdravilo Cosentyx zmanjšuje vnetje in druge simptome bolezni.
Concomitant immunosuppressive therapy
Sočasno imunosupresivno zdravljenje
The powder for solution for injection must be reconstituted before use.
Prašek za raztopino za injiciranje je treba pred uporabo rekonstituirati.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately.
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj, razen če metoda rekonstitucije izključuje tveganje za kontaminacijo z mikrobi.
Allow the vial to stand undisturbed at room temperature for approximately 5 minutes.
Vialo pustite mirovati na sobni temperaturi približno 5 minut.
Effect of weight on pharmacokinetics Secukinumab clearance and volume of distribution increase as body weight increases.
Vpliv telesne mase na farmakokinetiko Očistek in volumen porazdelitve sekukinumaba se povečujeta z večanjem telesne mase.
If you have forgotten to inject a dose of Cosentyx, inject the next dose as soon as you remember.
Če ste si pozabili injicirati odmerek zdravila Cosentyx, si naslednji odmerek injicirajte takoj, ko to ugotovite.
Forty percent of the participants in studies 1 and 2 completed the Psoriasis Symptom Diary©.
Štirideset odstotkov preiskovancev v 1. in 2. študiji je izpolnjevalo dnevnik simptomov psoriaze (Psoriasis Symptom Diary©).
What Cosentyx is and what it is used for
Kaj je zdravilo Cosentyx in za kaj ga uporabljamo
Table 3 Summary of clinical response on psoriasis study 2 (FIXTURE)
Preglednica 3 Pregled kliničnih odzivov v 2. študiji psoriaze (v študiji FIXTURE)
It is not known whether secukinumab is excreted in human milk.
Ni znano, ali se sekukinumab izloča v materino mleko.
Patients should be instructed to inject the full amount of Cosentyx according to the instructions provided in the package leaflet.
Bolnikom je treba naročiti, naj si injicirajo celotno količino zdravila Cosentyx po navodilih v priloženem Navodilu za uporabo.
• if you are receiving any other treatment for psoriasis, such as another immunosuppressant or phototherapy with ultraviolet (UV) light.
• če prejemate še katerega od zdravil za psoriazo, kot so druga imunosupresivna zdravila, ali se zdravite s fototerapijo (obsevanjem z ultravijoličnimi (UV) žarki).
Based on population pharmacokinetic analysis with a limited number of elderly patients (n=71 for age ≥65 years and n=7 for age ≥75 years), clearance in elderly patients and patients less than 65 years of age was similar.
Po rezultatih analize populacijske farmakokinetike pri majhnem številu starejših bolnikov (n=71 za starost ≥65 let in n=7 za starost ≥75 let) je bil očistek pri starejših bolnikih podoben kot pri bolnikih, ki so bili stari manj kot 65 let.
Patients randomised to “retreatment as needed” did not achieve adequate maintenance of response and therefore a fixed monthly maintenance regimen is recommended.
Pri bolnikih, ki so bili randomizirani na zdravljenje po režimu "ponovitve zdravljenja po potrebi", se odziv na zdravljenje ni ohranil v zadostni meri, zato se priporoča zdravljenje po vzdrževalnem režimu z rednim mesečnim odmerjanjem zdravila.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
Zdravilo Cosentyx je namenjeno uporabi po navodilih in pod nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere je indicirano zdravilo Cosentyx.
Other medicines and Cosentyx
Druga zdravila in zdravilo Cosentyx
Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks.
Pri tistih bolnikih, pri katerih sprva pride le do delnega odziva, se ta lahko kasneje izboljša, če bolnik prejema zdravilo več kot 16 tednov.
Figure 1 Time course of percentage change from baseline of mean PASI score in study 1 (ERASURE)
Slika 1 Časovni potek odstotne spremembe povprečne vrednosti indeksa PASI od izhodišča v 1. študiji (študiji ERASURE)
• burning sensation when passing urine.
• pekočo bolečino pri odvajanju urina.
In a study in subjects with plaque psoriasis, no interaction was observed between secukinumab and midazolam (CYP3A4 substrate).
V študiji pri bolnikih s psoriazo v plakih niso opažali nobenih interakcij med sekukinumabom in midazolamom (substrat CYP3A4).
Immunoglobulins are excreted in human milk and it is not known if secukinumab is absorbed systemically after ingestion.
Imunoglobulini se izločajo v materino mleko, ni pa znano, ali se sekukinumab po zaužitju sistemsko absorbira.
Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells.
Sekukinumab je rekombinantno popolnoma humano monoklonsko protitelo, pridobljeno s pomočjo ovarijskih celic kitajskega hrčka (celic CHO).
• lower respiratory tract infections
• okužbe spodnjih dihal,
If an anaphylactic or other serious allergic reactions occur, administration of secukinumab should be discontinued immediately and appropriate therapy initiated.
Če pride do anafilaktičnih ali drugih resnih alergijskih reakcij, je treba zdravljenje s sekukinumabom takoj prekiniti in uvesti ustrezno zdravljenje.
(nasopharyngitis, rhinitis)
(nazofaringitis in rinitis).
In psoriasis phase 3 clinical studies, neutropenia was more frequently observed with secukinumab than with placebo, but most cases were mild, transient and reversible.
V kliničnih študijah psoriaze faze 3 so nevtropenijo pri uporabi sekukinumaba opažali pogosteje kot pri uporabi placeba, vendar je bila v večini primerov blago izražena, prehodna in reverzibilna.
• warm, red and painful skin, or a painful skin rash with blisters
• vročo, rdečo in bolečo kožo ali boleč kožni izpuščaj z mehurčki,
Cosentyx is used for the treatment of the following inflammatory diseases:
Zdravilo Cosentyx uporabljamo pri zdravljenju naslednjih vnetnih bolezni:
• if you have recently had a vaccination or if you are due to have a vaccination during treatment with Cosentyx.
• če ste bili pred kratkim cepljeni ali če morate prejeti cepivo v času zdravljenja z zdravilom
IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
IL-17A je naravno prisoten citokin, ki sodeluje pri normalnem vnetnem in imunskem odzivu.
Table 4 Summary of clinical response on CLEAR study
Preglednica 4 Pregled kliničnih odzivov v študiji CLEAR
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
V primeru prevelikega odmerjanja je priporočeno bolnika opazovati glede morebitnega pojavljanja znakov ali simptomov neželenih učinkov in v tem primeru takoj uvesti simptomatsko zdravljenje.
ASAS 5/6, %
odziv ASAS 5/6, %
For other psoriatic arthritis patients:
Za druge bolnike s psoriatičnim artritisom:
Consideration should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment.
Pri bolnikih, pri katerih v 16 tednih zdravljenja ne pride do odziva, je treba razmisliti o prenehanju zdravljenja.
Because of the potential for adverse reactions in nursing infants from secukinumab, a decision on whether to discontinue breast-feeding during treatment and up to 20 weeks after treatment or to discontinue therapy with Cosentyx must be made taking into account the benefit of breast-feeding to the child and the benefit of therapy to the woman.
Zaradi možnosti razvoja neželenih učinkov sekukinumaba pri dojenem otroku se je treba odločiti, ali bo bolnica prenehala z dojenjem v času zdravljenja in obdobju 20 tednov po zaključku zdravljenja ali bo prekinila zdravljenje z zdravilom Cosentyx, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Patients receiving secukinumab may receive concurrent inactivated or non-live vaccinations.
Bolniki, ki prejemajo sekukinumab, so lahko sočasno cepljeni z inaktiviranimi ali drugimi cepivi, ki niso živa.
Animal studies have not been conducted to evaluate the carcinogenic potential of secukinumab.
Za oceno kancerogenega potenciala sekukinumaba niso izvajali študij na živalih.
CARTON - vial
ŠKATLA - viala
Do not shake or invert the vial.
Viale ne stresajte in ne obračajte.
Neutropenia <1.0-0.5x10
O nevtropeniji z vrednostmi <1,0-0,5 x 10
For both studies, the primary endpoint was at least a 20% improvement in Assessment of Spondyloarthritis International Society (ASAS 20) criteria at week 16.
V obeh študijah je bil primarni cilj študije najmanj 20-odstotno izboljšanje ocene ASAS (ASAS 20) po kriterijih Mednarodnega združenja za spondiloartritis (ASAS - Assessment of Spondyloarthritis International Society) po 16 tednih zdravljenja.
IgGs are mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance of secukinumab.
Protitelesa IgG se izločajo večinoma s pomočjo katabolizma in ni pričakovati, da bi okvara jeter lahko vplivala na izločanje sekukinumaba iz telesa.
Patients in Ankylosing Spondylitis study 1 (AS study 1) and Ankylosing Spondylitis study 2 (AS study 2) had a diagnosis of AS for a median of 2.7 to 5.8 years.
Pri bolnikih v študiji ankilozirajočega spondilitisa 1 (AS študiji 1) in študiji ankilozirajočega spondilitisa 2 (AS študiji 2) je bila mediana časa od postavitve diagnoze ankilozirajočega spondilitisa 2,7 do 5,8 let.